Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
43.32%
Operating Margin
19.40%
Net Margin
14.80%
Efficiency Metrics
Revenue per Expense Ratio
1.24
R&D as % of Revenue
2.79%
Earnings Quality
EBITDA Margin
22.44%
Income Tax Rate
12.41%
EPS
6.1500000000
Balance Sheet Analysis
Current Ratio
1.26
Cash Ratio
0.43
Working Capital
$281.20M
Debt to Equity
1.53
Debt to Assets
46.74%
Equity Ratio
30.58%
Cash Flow Analysis
Operating Cash Flow Ratio
16.45%
Free Cash Flow Ratio
14.14%
CapEx to Revenue
2.31%
Dividends Paid
$158.70M
Stock Buybacks
$59.90M
Total Shareholder Returns
$218.60M
Cash Position Change
62.53%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 10.41%
Increased R&D investment by 36.78%
Detailed Growth Metrics
Core Performance
Revenue
11.58%
Net Income
17.99%
EPS
18.27%
Operating Income
20.80%
Operational Efficiency
R&D Expenses
36.78%
SG&A Expenses
17.61%
Operating Cash Flow
30.71%
Free Cash Flow
30.57%
Balance Sheet Health
Assets
8.03%
Debt
-3.80%
Book Value per Share
39.74%
Inventory
-8.46%
Shareholder Returns
Dividends per Share
10.41%
Shares Outstanding
-0.11%
Long Term Trends
3Y Revenue/Share
40.94%
5Y Revenue/Share
44.44%
3Y Dividend/Share
42.07%
5Y Dividend/Share
116.02%